Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749788 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels
A Phase 2 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00749788 is a Phase 2 study that has completed, run by Akros Pharma. The registered enrollment target is 150 participants.
The verdict
NCT00749788, a Phase 2 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.
Interventions
- DRUG Placebo
- DRUG JTT-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749788
The ClinicalTrials.gov registry entry for NCT00749788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00749788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749788 about?
NCT00749788 is a clinical study titled "Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels". The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.
What is the current status of trial NCT00749788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-12. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00749788?
The interventions under investigation include: Placebo (DRUG), JTT-302 (DRUG).
Who is sponsoring clinical trial NCT00749788?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.